Literature DB >> 11734100

Progressive Myoclonic Epilepsies.

Basim M. Uthman1, Andreas Reichl.   

Abstract

The treatment of progressive myoclonus epilepsy (PME) remains a major therapeutic challenge in neurology. Generalized convulsive seizures are often well controlled through classic antiepileptic drugs (AEDs) like valproate and clonazepam, whereas myoclonus, the main symptom that is affecting patients most in their daily life, is usually refractory to standard AEDs. Alternative therapy concepts have been and still are investigated. Among the new drugs, zonisamide and piracetam have shown the most promising results as add-on treatments. Other therapeutic approaches, like the use of antioxidants, 5-hydroxytryptophan (5-HTP), and baclofen should also be taken into consideration for the treatment of intractable cases of PME. Nonpharmacologic treatment options such as diet and physical therapy should always be considered, because they may save costs and side effects. In some instances, the occasional use of alcohol has shown beneficial effects.

Entities:  

Year:  2002        PMID: 11734100     DOI: 10.1007/s11940-002-0001-9

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  46 in total

1.  Progressive myoclonic epilepsies syndrome (Ramsay Hunt syndrome) with mental disorder: report of two cases.

Authors:  M C Hsiao; C Y Liu; Y Y Yang; C S Lu; E K Yeh
Journal:  Psychiatry Clin Neurosci       Date:  1999-10       Impact factor: 5.188

2.  Clonazepam.

Authors:  T R Browne
Journal:  N Engl J Med       Date:  1978-10-12       Impact factor: 91.245

Review 3.  Zonisamide.

Authors:  I E Leppik
Journal:  Epilepsia       Date:  1999       Impact factor: 5.864

4.  Impaired intestinal absorption of biotin in juvenile multiple carboxylase deficiency.

Authors:  J G Thoene; R Lemons; H Baker
Journal:  N Engl J Med       Date:  1983-03-17       Impact factor: 91.245

5.  Effect of sodium valproate on phenobarbital serum levels in children and adults.

Authors:  M R Fernandez de Gatta; A C Alonso Gonzalez; M J Garcia Sanchez; A Dominguez-Gil Hurle; J Santos Borbujo; L Monzon Corral
Journal:  Ther Drug Monit       Date:  1986       Impact factor: 3.681

6.  Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo.

Authors:  M Koskiniemi; B Van Vleymen; L Hakamies; S Lamusuo; J Taalas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

7.  Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex.

Authors:  G Lees; M J Leach
Journal:  Brain Res       Date:  1993-05-28       Impact factor: 3.252

Review 8.  The clinical challenge of progressive myoclonus epilepsy.

Authors:  E Tate
Journal:  Nurse Pract       Date:  1993-05

9.  Valproate and clonazepam in the treatment of severe progressive myoclonus epilepsy.

Authors:  M Iivanainen; J J Himberg
Journal:  Arch Neurol       Date:  1982-04

10.  Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy.

Authors:  L M Ojemann; R A Shastri; A J Wilensky; P N Friel; R H Levy; J R McLean; R A Buchanan
Journal:  Ther Drug Monit       Date:  1986       Impact factor: 3.681

View more
  2 in total

Review 1.  The Finnish Disease Heritage III: the individual diseases.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

Review 2.  Drug Treatment of Progressive Myoclonic Epilepsy.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.